文献速递关节外科

血清淀粉样蛋白A是筛查假体周围关节感染的有前景工具

Serum Amyloid A Is a Promising Tool for Screening Periprosthetic Joint Infection.
PubMed 文献 · Clin Orthop Relat Res · 2025-05-16

这项回顾性诊断研究纳入109例翻修全髋或全膝关节置换术患者,评估血清淀粉样蛋白A诊断假体周围关节感染(PJI)的效能。血清淀粉样蛋白A在 cut-off 值为14时灵敏度85%、特异度96%,其AUC(0.96)优于血沉(0.85)和纤维蛋白原(0.84),与C反应蛋白(0.93)无差异。作者认为血清淀粉样蛋白A是筛查PJI的高准确度生物标志物。

要点

  • 血清淀粉样蛋白A诊断PJI的AUC为0.96,优于血沉的0.85和纤维蛋白原的0.84。
  • 血清淀粉样蛋白A与C反应蛋白的AUC(0.96 vs 0.93)无显著差异(p=0.17)。
  • 以14为cut-off值,血清淀粉样蛋白A灵敏度85%、特异度96%、阳性预测值96%、阴性预测值83%。

核心结论

  • 血清淀粉样蛋白A是筛查PJI的高准确度生物标志物,性能优于血沉和纤维蛋白原,与C反应蛋白相当。
  • 作者认为血清淀粉样蛋白A可为外科医生筛查疑似PJI提供新工具,尤其在C反应蛋白和血沉结果不明确或需要快速决策时。

研究设计与样本

  • 回顾性诊断研究,纳入2020年10月至2023年10月由三位外科医生实施的137例翻修全髋或全膝关节置换术中的109例(80%)进行分析。
  • 排除28例(20%),原因包括再植入、血液生物标志物数据缺失和假体周围骨折。
  • 按2018年改良MSIS标准分为PJI组62例和非PJI组47例,非PJI组47例翻修术后随访至少1年以确认无假阴性,期间无失访。

主要发现

  • PJI组男性占56%(中位年龄66岁),涉及23髋和39膝;非PJI组男性占17%(中位年龄66岁),涉及25髋和22膝。
  • 基于约登指数确定的cut-off值14,血清淀粉样蛋白A诊断PJI的灵敏度为85%(95%CI 74%至93%),特异度为96%(95%CI 86%至100%)。
  • 血清淀粉样蛋白A的阳性预测值为96%(95%CI 87%至99%),阴性预测值为83%(95%CI 73%至90%)。
  • 血清淀粉样蛋白A的AUC为0.96,高于血沉的0.85(p=0.005)和血浆纤维蛋白原的0.84(p=0.002)。
  • 血清淀粉样蛋白A与C反应蛋白的AUC(0.96 vs 0.93)无显著差异(p=0.17)。

关键数值与推荐

  • PJI诊断采用2018年改良MSIS标准。
  • 血清淀粉样蛋白A以14为cut-off值(基于约登指数),灵敏度85%(95%CI 74%至93%),特异度96%(95%CI 86%至100%)。
  • 血清淀粉样蛋白A阳性预测值96%(95%CI 87%至99%),阴性预测值83%(95%CI 73%至90%)。
  • 血清淀粉样蛋白A的AUC为0.96,血沉为0.85(p=0.005),血浆纤维蛋白原为0.84(p=0.002),C反应蛋白为0.93(p=0.17)。

临床怎么用

  • 作者认为血清淀粉样蛋白A可作为筛查疑似PJI的高准确度生物标志物,尤其适用于C反应蛋白和血沉结果不明确或需要快速决策时。
  • 作者指出血清淀粉样蛋白A具有快速动力学、成本效益、周转时间短和高特异度的特点,可减少诊断延迟。

局限性

  • 本研究未对PJI亚型进行分层。
  • 未来需大规模多中心研究在不同患者人群中验证这些发现,并建立急性和慢性PJI表现的亚型特异性诊断阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the modified Musculoskeletal Infection Society (MSIS) criteria are commonly used, the accurate and timely diagnosis of periprosthetic joint infection (PJI) remains challenging. Serum amyloid A, like C-reactive protein (CRP), is an acute-phase reactant and widely serves as a diagnostic tool for infectious diseases in adults and children. However, the role of serum amyloid A in diagnosing PJI has not been fully explored. QUESTIONS/PURPOSES: (1) What were the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) of serum amyloid A as a diagnostic test for PJI? (2) How did the diagnostic performance of serum amyloid A compare with that of other commonly used serum biomarkers? METHODS: Between October 2020 and October 2023, three surgeons performed 137 revision THA or TKA procedures. All were considered potentially eligible, but we excluded 20% (28 of 137) because of reimplantation, missing blood biomarker data, and periprosthetic fracture, leaving 80% (109) for analysis in this retrospective study. Those were divided into two groups: those believed to have PJI (62) based on the modified 2018 MSIS criteria and those who did not meet 2018 MSIS criteria (non-PJI, n = 47). The PJI group comprised 56% males (median age 66 years) with 23 hips and 39 knees affected, while the non-PJI group included 17% males (median age 66 years) involving 25 hips and 22 knees. All 47 revisions in the non-PJI group were followed for at least 1 year to make sure that they were not false negatives. No patients were lost to follow-up during this period. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curve analysis. Sensitivity, specificity, PPV, NPV, and AUC were calculated for all four routine tests (serum amyloid A, CRP, erythrocyte sedimentation rate [ESR], and fibrinogen) to determine their diagnostic capacity for PJI. RESULTS: For the diagnosis of PJI, with a cutoff value of 14 based on the Youden index, serum amyloid A had a sensitivity of 85% (95% confidence interval [CI] 74% to 93%), a specificity of 96% (95% CI 86% to 100%), a PPV of 96% (95% CI 87% to 99%), and an NPV of 83% (95% CI 73% to 90%). Using the optimal cutoffs for the AUC of the ROC as calculated by the Youden index for each test, serum amyloid A was more accurate than the ESR (0.96 versus 0.85; p = 0.005) and plasma fibrinogen (0.96 versus 0.84; p = 0.002) but no different from the CRP (0.96 versus 0.93; p = 0.17). CONCLUSION: Our study established serum amyloid A as a promising high-accuracy biomarker for PJI screening, demonstrating superior performance to ESR and fibrinogen while being comparable with the diagnostic performance of CRP. This provides surgeons with a novel tool for screening suspected PJI, particularly when interpreting ambiguous CRP and ESR results or requiring rapid decision-making, as its combination of rapid kinetics, cost-efficiency, short turnaround time, and high specificity reduce diagnostic delays. While our findings demonstrate promise, this study did not stratify PJI subtypes. Future large-scale multicenter studies should validate these findings across diverse patient populations and establish subtype-specific diagnostic thresholds for acute and chronic PJI presentations. LEVEL OF EVIDENCE: Level III, diagnostic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Zhang X, Lu F, Geng B, et al. Serum Amyloid A Is a Promising Tool for Screening Periprosthetic Joint Infection. Clin Orthop Relat Res. 2025. PMID: 40388800. doi:10.1097/CORR.0000000000003547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。